Skip to main content
    C

    Calidi Biotherapeutics Inc. (CLDI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.87
    -0.00 (-0.47%)

    Market Cap: $3.21M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    33%(3/9)
    Avg Surprise
    -67.11%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 13
    		$-2.94N/AN/ABeat-988.9%
    Sep 25
    Reported Nov 13
    		$-2.21$-1.68-31.55%Miss+71.7%
    Jun 25
    Reported Aug 8
    		$-1.99$-1.32-50.76%Miss+88.2%
    Mar 25
    Reported Apr 4
    		$-2.25$-1.80-25.00%Miss+90.5%
    Dec 24
    Reported Mar 31
    		$-0.27$-0.09-200.00%Miss+43.7%
    Sep 24
    Reported Nov 12
    		$-7.80$-10.26+23.98%Beat+87.7%
    Jun 24
    Reported Aug 13
    		$-16.80$-17.40+3.45%Beat-3788.0%
    Mar 24
    Reported May 14
    		$-23.71$-32.40+26.82%Beat+12.3%
    Dec 23
    Reported Mar 19
    		$-0.48$-0.20-140.00%Miss-84.6%
    Sep 23
    Reported Nov 14
    		$-63.43$-20.40-210.93%Miss-317250.0%
    Jun 23
    Reported Aug 30
    		$-0.43N/AN/ABeat-408.6%
    Mar 23
    Reported Jun 28
    		$-27.02N/AN/ABeat-54148.2%
    Dec 22
    Reported Mar 30
    		$-0.26$0.00N/AMiss-273.3%
    Sep 22
    Reported Nov 14
    		$0.02$0.00N/ABeat+166.7%
    Jun 22
    Reported Sep 28
    		$0.14$0.00N/ABeat-
    Mar 22
    Reported Jun 28
    		$0.05$0.00N/ABeat-
    Dec 21
    Reported Mar 29
    		$0.15$0.00N/ABeat-
    Sep 21
    Reported Dec 29
    		$-0.03$0.00N/AMiss-
    Jun 21
    Reported Sep 28
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCF-0.07xFCF Yield-1448.72%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-672.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-112.69x
    Current Ratio1.68xQuick Ratio1.68x
    Trading Statistics
    Beta1.33Avg Volume209.66K
    52-Week High$27.0452-Week Low$0.82

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.98
    SMA 20$1.04
    SMA 50$1.25
    SMA 200$5.41
    EMA 10$0.97
    EMA 20$1.04
    EMA 50$1.32
    EMA 200$9.39

    MACD

    Line: -0.11Signal: -0.10Hist: -0.01

    ADX

    ADX: 25.6+DI: 8.5-DI: 23.2

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$1.30

    Bollinger Bands

    Upper Band$1.22
    Lower Band$0.87
    %B Position3315%(Upper)
    Band Width-0.00

    RSI (14-Day)

    Oversold
    26.2

    Momentum Oscillators

    Stoch %K11.6
    Stoch %D9.1
    Williams %R-83.9
    ROC (10d)-19.5%
    Momentum-0.21
    CCI (20d)-171.5
    MFI (14d)22.1

    Volatility Measures

    ATR (14d)$0.11(13.0%)
    StdDev (20d)0.09
    Hist Vol73.8%(High)

    Volume Flow

    VWAP$0.87
    OBV629.1M
    AD Line911.4B
    CMF (20d)-0.152

    Volume Metrics

    Avg Vol (20d)219.5K
    Vol Ratio0.1x(Low)
    VWMA (20d)$1.09

    Pivot Points

    R3$1.02
    R2$0.97
    R1$0.92
    Pivot Point$0.87
    S1$0.82
    S2$0.77
    S3$0.72

    Advanced Oscillators

    TSI-36.52
    Ultimate Osc43.5
    KST-214.70

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.50M$0$0$0$0$0
    Cost of Revenue$0$0$423,000$0$0$0$393,000$0$0$0$364,000$0
    Gross Profit$0$0$-423,000$0$0$0$-393,000$0$0$0$-364,000$0
    Operating Expenses$4.15M$4.19M$4.47M$5.05M$5.66M$5.06M$4.03M$5.23M$5.77M$6.75M$9.82M$7.22M
    R&D$2.56M$2.59M$2.36M$2.36M$2.59M$2.42M$1.81M$2.15M$2.17M$2.74M$0$3.25M
    SG&A$1.59M$1.60M$2.11M$2.69M$3.07M$2.64M$2.21M$3.07M$3.60M$4.01M$0$3.97M
    Operating Income$-4,150,000$-4,187,000$-4,466,000$-5,048,000$-5,664,000$-5,062,000$-4,026,000$-5,226,000$-5,772,000$-6,752,000$-9,820,000$-7,221,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$35,000$38,000$42,000$41,000$52,000$72,000$175,000$232,000$273,000$253,000$0$795,000
    Income Before Tax$-4,155,000$-4,104,000$-4,061,000$-5,171,000$-5,757,000$-5,059,000$-4,145,000$-5,070,000$-5,759,000$-7,221,000$-8,232,000$-2,013,000
    Income Tax Expense$5,000$4,000$-2,000$10,000$4,000$3,000$3,000$-1,000$8,000$4,000$-3,000$11,000
    Net Income$-4,160,000$-4,108,000$-4,059,000$-5,181,000$-5,761,000$-5,062,000$-4,148,000$-5,069,000$-5,767,000$-7,225,000$-8,229,000$-2,024,000
    EBITDA$-3,682,000$-3,640,000$-3,840,000$-4,703,000$-5,298,000$-4,593,000$-3,573,000$-4,439,000$-5,092,000$-6,578,000$-9,735,000$-672,000
    EBIT$-4,120,000$-4,066,000$-4,263,000$-5,130,000$-5,705,000$-4,987,000$-3,970,000$-4,838,000$-5,486,000$-6,968,000$-9,820,000$-1,218,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CLDI

    News

    Enterprise value to EBITDA forward of Calidi Biotherapeutics Inc. – OTC:CLDWW

    This article provides a financial data point for Calidi Biotherapeutics Inc. (OTC:CLDWW), specifically its enterprise value to EBITDA forward. The content is concise and directly presents this financial metric without...

    TradingView•10/1/26•Neutral

    Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Races to Fix an Equity Shortfall Before Delisting

    Calidi Biotherapeutics (NYSEAMERICAN:CLDI) received a noncompliance notice from NYSE American due to its stockholders' equity falling below the required $4.0 million minimum. As of June 30, 2026...

    kalkine.ca•9/28/26•Bearish

    Calidi Biotherapeutics gets NYSE compliance warning but stock surprises

    Calidi Biotherapeutics announced it received a NYSE American compliance notice for not meeting the $4M minimum stockholders’ equity requirement. Despite this warning...

    TradingView•9/25/26•Neutral

    Calidi Biotherapeutics Received Notice of Noncompliance

    Calidi Biotherapeutics (CLDI) received a notice from NYSE American on September 21, 2026, indicating noncompliance with Section 1003(a)(ii). The noncompliance is due to stockholders' equity of $3.1 million...

    TradingView•9/25/26•Bearish

    Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency

    Calidi Biotherapeutics (NYSE American: CLDI) announced it received a notification from NYSE American regarding non-compliance with continued listing standards due to stockholders' equity deficiency. The company must...

    GlobeNewswire•9/25/26•Bearish

    CLDI Valuation and Fair Value

    P/FCF
    -0.1x
    P/B
    0.4x
    See GNG's fair value

    CLDI Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -672.0%
    FCF yield
    -1448.7%

    CLDI Competitors

    CompanyTicker
    IO Biotech IncIOBT
    Clearmind Medicine Inc. Common SharesCMND
    Mainz Biomed BVMYNZ
    60 Degrees Pharmaceuticals, Inc. Common StockSXTP
    Sunshine Biopharma IncSBFM
    Cadrenal Therapeutics, Inc. Common StockCVKD
    Eocene Ltd.EOCN
    Mustang Bio IncMBIO

    Sector: Healthcare

    CLDI Bull Case vs Bear Case

    Bear case

    • CLDI beat EPS estimates in 37.5% of its last 8 reported quarters.

    CLDI Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -49.1%

    Frequently Asked Questions About CLDI

    Does CLDI pay dividends?

    Calidi Biotherapeutics Inc. (CLDI) does not currently pay a regular dividend.

    What is CLDI's market cap?

    Calidi Biotherapeutics Inc. (CLDI) has a market capitalization of $3.21M with a current stock price of $0.87.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In